Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.

× No keyword cloud information.

5 in total

1. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.

Authors: Gerald Schulman; Tomas Berl; Gerald J Beck; Giuseppe Remuzzi; Eberhard Ritz; Kiyoshi Arita; Akira Kato; Miho Shimizu
Journal: J Am Soc Nephrol Date: 2014-10-27 Impact factor: 10.121

2. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.

Authors: Kenichi Tanaka; Masaaki Nakayama; Makoto Kanno; Hiroshi Kimura; Kimio Watanabe; Yoshihiro Tani; Yoshimitsu Hayashi; Koichi Asahi; Hiroyuki Terawaki; Tsuyoshi Watanabe
Journal: Clin Exp Nephrol Date: 2015-02-13 Impact factor: 2.801

3. Disulfide S-monoxides convert xanthine dehydrogenase into oxidase in rat liver cytosol more potently than their respective disulfides.

Authors: Satoru Sakuma; Junko Fujita; Masahiko Nakanishi; Shun-ich Wada; Yohko Fujimoto
Journal: Biol Pharm Bull Date: 2008-05 Impact factor: 2.233

4. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.

Authors: Takashi Nakamura; Takayo Murase; Mai Nampei; Nobutaka Morimoto; Naoki Ashizawa; Takashi Iwanaga; Ryusuke Sakamoto
Journal: Eur J Pharmacol Date: 2016-03-30 Impact factor: 4.432

5. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.

Authors: Tatsuo Hosoya; Iwao Ohno; Shinsuke Nomura; Ichiro Hisatome; Shunya Uchida; Shin Fujimori; Tetsuya Yamamoto; Shigeko Hara
Journal: Clin Exp Nephrol Date: 2014-01-22 Impact factor: 2.801

5 in total

2 in total

1. Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease.

Authors: Hirotaka Saito; Kenichi Tanaka; Tsuyoshi Iwasaki; Akira Oda; Shuhei Watanabe; Makoto Kanno; Hiroshi Kimura; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal: Sci Rep Date: 2021-01-14 Impact factor: 4.379

2. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.

Authors: Kazuomi Kario; Masafumi Nishizawa; Mari Kiuchi; Arihiro Kiyosue; Fumishi Tomita; Hiroshi Ohtani; Yasuhisa Abe; Hideyo Kuga; Satoshi Miyazaki; Takatoshi Kasai; Makiko Hongou; Takanori Yasu; Jin Kuramochi; Yoshihiro Fukumoto; Satoshi Hoshide; Ichiro Hisatome
Journal: J Clin Hypertens (Greenwich) Date: 2021-01-05 Impact factor: 3.738

2 in total